A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
Vetoquinol - makers of the NSAID Cimalgex - has announced the launch of its updated website www.CiMyDog.co.uk.
The company says the website has been developed to provide reliable online information about pain in dogs to cater for the increasing needs of pet owners and vets.
The website has two sections. The first is a pet owner focussed, educational tool which takes the visitor on a journey through the process of pain; from spotting the signs of pain all the way through to ways of relieving pain, culminating in the recommendation that the visitor seeks advice from their veterinary practice.
The second section requires registration as it contains more in depth information on the pain process and potential treatment options available, this section is for veterinary professionals only. Also on this section of the website there are many scientific abstracts related to pain and treatment with links to enable the veterinary visitor can view this peer reviewed material.
Robert Simpson, Cimalgex Product Manager said: "The internet is a very powerful tool in terms of increasing education, especially in areas such as canine pain. Unfortunately there can also be a lot of misinformation online and so we felt it was important for Vetoquinol to try and redress the balance by producing www.CiMyDog.co.uk. This can be used as a reliable and up-to-date resource by pet owners and veterinary professionals alike. -
www.CiMyDog.co.uk is a very interactive site which aims to demystify the pain treatment process, ensure pet owners look out for behavioural signs of pain and looks to improve overall canine health with assistance from their veterinary practice. We hope that this will be a valuable resource to which vets can refer their pet owners."
The RCVS Disciplinary Committee has refused an application for restoration to the Register by Mr Joseph Holmes, who was struck off in 2011 for serious professional misconduct associated with surgery he had carried out on a dog and two cats.
At a two-week Disciplinary Committee hearing that concluded on 14 January 2011, two separate complaints had been considered against Mr Holmes, formerly of Waltham Veterinary Clinic, Grimsby. These involved a total of 31 charges, of which 28 were found to amount to serious professional misconduct. Mr Holmes was found to have advised on and undertaken surgical procedures without sufficient clinical grounds or consideration of alternative treatment options; failed to obtain the informed consent of his clients; undertaken procedures outside his area of competence; failed to refer or discuss the option of referral to a specialist; and, failed to provide his patients with adequate pain relief.
The then-Committee directed Mr Holmes' name be removed from the Register, whereupon he appealed to the Privy Council, who dismissed his appeal on 22 December 2011, concluding that removal from the Register "was the only disposal which could properly reflect the primary need to serve both the interests of animal welfare and the reputation of the veterinary profession".
At the hearing last week the Committee considered several factors in relation to Mr Holmes' application for restoration. Although Mr Holmes gave assurances that he accepted the findings of the original hearing, this contrasted completely to the robust way in which he had challenged all of these at that hearing and the majority in his appeal. Mr Holmes had been off the Register for only 12 months - just over the minimum period before an application for restoral was permitted. The Committee took the view that the application was premature and was not satisfied that Mr Holmes truly appreciated the seriousness of the findings made against him.
In response to questions from the Committee, Mr Holmes showed deficiencies in his knowledge, such as not knowing all of the constituents of the human drug, Anadin Extra, in spite of having produced a record of continuing professional development (CPD) on analgesia and having prescribed it to a dog in the original complaint. He did not provide records of CPD for 2010, 2011 and 2012, and although recognising that working in isolation from the majority of his fellow practitioners had contributed to his failures, he had made very limited efforts to observe first-opinion veterinary practice.
The Committee accepted at face value Mr Holmes' statement that he had not worked as a veterinary surgeon whilst de-registered, and accepted that removal from the Register had had a profound effect on Mr Holmes and his family, including the sale of his practice. It noted that Mr Holmes produced only the testimonials previously submitted to the Privy Council, which were of limited scope.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "Having regard to all the factors set out above, the Committee regrets that it is not satisfied that the applicant is fit to be restored to the Register. Accordingly, the application is refused."
The Animal Health Trust's (AHT) Dr Sue Dyson has been awarded a place in the International Equine Veterinarians Hall of Fame, in recognition of her contribution to hoof care in horses.
Sue, who is Head of Clinical Orthopaedics at the AHT, has lectured internationally and is known for both her clinical work with horses and an extensive research record, having published more than 200 refereed papers on lameness and diagnostic imaging in scientific journals. She has also co-authored several veterinary textbooks as well as training and competing as a high-level rider in international events.
Established in 1997, the International Equine Veterinarians Hall of Fame honours veterinary surgeons who have contributed to the knowledge and recognition of proper hoof care for horses. Vets are nominated either as practicing equine vets who work closely with farriers in the field, or as college and industry vets involved in teaching, research or other important aspects of equine veterinary and hoof care.
Anyone can nominate an equine vet for the award, which is sponsored by the American Farriers Journal, but selection is completed by previous inductees into the International Equine Veterinarians Hall of Fame. Awards are presented each year during the International Hoof-Care Summit in Cincinnati, Ohio.
Sue said: "I was completely surprised, but absolutely thrilled, to learn that I had been selected to join the distinguished list of people who have previously been appointed to the International Equine Veterinarians Hall of Fame.
"I think it is very humbling to recognise that, despite the knowledge that my team and I have amassed in the last 30 years, there is so much more to learn. From every new finding come many more questions. I hope that the enthusiastic dedication of my team will continue to result in learning and discovering more, and inspire others to do likewise, to the ultimate benefit of the welfare of our great friend, the horse."
Sue has has worked at the AHT for 30 years and is currently researching the association between hindlimb lameness and saddle slip. She has observed some association between the two for several years, however saddle slip has traditionally been attributed to an ill-fitting saddle, asymmetry of the horse's back shape or a crooked rider.
In 2011 Sue carried out a prospective research project with Intern Line Greve: 'Saddle slip may be an indicator of the presence of hindlimb lameness'. It was presented at the 51st Annual Congress of the British Equine Veterinary Association, Birmingham 2012, and identified that in some cases, saddle slip was directly linked to the presence of hindlimb lameness.
Research results showed that of 128 horses assessed for lameness grade and degree of saddle slip when ridden by two riders, the saddle consistently slipped to one side in 54% of the horses with hindlimb lameness, in comparison to just 4% of the horses with forelimb lameness. Diagnostic analgesia to abolish the hindlimb lameness eliminated the saddle slip in 97% of the horses observed in the study.
Sue and Line are currently undertaking further research to measure movement of the back, and forces under the saddle, with the aim of explaining biomechanically what is happening during the occurrence of saddle slip.
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
References
1. 1987 (Taranaki, North Island)
Ceva Animal Health has launched a new TV advertising campaign designed to raise awareness of problems owners may face in a multi-cat environment.
The Cat Cabin Fever campaign will run for four weeks.
Ceva says the 20 second TV ads have been designed to strike a chord with viewers who have more than one cat in their household, where 'sometimes sharing just isn't an option'. Highlighted in particular is the Feliway Diffuser which releases natural pheromones into a room to help cats feel at ease, allowing them to cope with stressful situations and prevent unwanted behaviour. Malcolm Laurie, head of marketing at Ceva, said: "We know that there are more than 8million cats in the UK and only 2.5million cat households, therefore the majority of households must have more than one cat. "However, cats are solitary animals, which makes living with other cats difficult at times. This campaign is focused on making the lives of cat owners and their pets as harmonious as possible, including lots of top tips on how to ease any tensions in such an environment." Ceva has also produced a multi-cat leaflet designed to give owners specific advice on how to provide the correct environment for our feline friends The advertising campaign will be supported by online competitions, marketing materials for veterinary clinics and retailers, which include a checklist for a cat friendly home, and PR. For more information, visit: http://www.feliway.co.uk/.
The RCVS Disciplinary Committee has directed that a Leeds-based veterinary surgeon, whose convictions for threatening behaviour, theft, and assault made him unfit to practise, should be removed from the Register.
At the outset of the two-day hearing, Dr Gary Samuel admitted his convictions. These related to his actions near his property in Cardiff on 10 July 2011, and were received at Cardiff Magistrates' Court on 22 November 2011. The Committee was asked to decide if these convictions made Dr Samuel unfit to practise veterinary surgery, and to decide upon any sanction.
The facts of the offences, as set out at the magistrates' court by the prosecution, were that Dr Samuel took a camera and memory card from a neighbour who was taking photographs of construction works behind his property. In doing so, he grabbed the neighbour from behind, twisting her arm, and later threatened her and her partner with a large piece of wood.
Although Dr Samuel wrote to the College saying he had pleaded guilty to the charges, he also denied some of the offences charged, suggesting that it was the neighbour who had been abusive towards him.
The Committee allowed the possibility that Dr Samuel was provoked by the taking of photographs and may have been subjected to offensive abuse by the neighbour, and considered that he acted impulsively and lost control of his actions. However, the convictions were for serious offences: the assault resulted in injury to the victim; the threatening behaviour involved a risk of injury to the victim and her partner; and, the theft involved dishonesty. Dr Samuel's conduct at the time was "reckless", and he had since displayed very limited insight into his behaviour.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The Committee considers that the offences of which the Respondent was convicted, and to which he pleaded guilty, were serious, as is reflected in the suspended sentences, community service orders, fines, restrictions and penalties imposed by the court. The Committee accepts that this is not a case in which the welfare of animals has been put at risk, but takes the view that a serious sanction is required in order to uphold the reputation of the veterinary profession, and public confidence in it, and to uphold proper standards of conduct and behaviour on the part of its members."
The Committee directed Dr Samuel's name should be removed from the Register.
Davies Veterinary Specialists (DVS), the private small animal referral centre based in Hertfordshire, has installed two new state-of-the-art ESAOTE ultrasound machines.
DVS says The MyLab Twice Vet and the MyLab Class C Vet provide fast, efficient and highly accurate imaging in a wide range of applications, including high-definition abdominal, cardiac, musculoskeletal and ophthalmic scans.
The MyLab Twice Vet, with its range of probes including the broadband 18MHz linear probe, will be used for general ultrasonographic imaging at DVS. It is capable of the most refined contrast media examinations that, for example, can help to locate and identify a liver tumour that may be rendered invisible when using conventional diagnostic procedures.
The MyLab Class C will be used predominantly for advanced cardiac work, including trans-oesophageal echocardiography for interventional procedures in theatre.
Pedro Oliveira, European Veterinary Specialist in Cardiology at DVS said: "The trans-oesophageal probe is currently a very rare piece of equipment in veterinary diagnostics. It gives us the capacity to obtain unique views of the heart, especially the heart base which can be a very difficult area to examine with regular echocardiography. It also allows real-time and direct monitoring of procedures, such as deployment of devices to occlude patent ductus arteriosus, surgery and anaesthesia in critical patients."
The first patient to benefit from the new My Lab Class C was an 11-year-old, female German shepherd dog with suspected cardiac neoplasia following several episodes of haemorrhage into the pericardium. A normal echocardiographic examination identified a small suspect area but it was in a part of the heart that was very difficult to approach surgically.
However, a trans-oesophageal examination revealed that another small mass close to the tip of the right auricle was actually the origin of the bleeding. The dog underwent surgery to remove the mass and subsequently made a full recovery. Without the My Lab Class C there would have been no viable options for this dog.
Clive Elwood, Managing Director at DVS, said: "Combining the best possible on-site diagnostic equipment with some of Europe's finest clinicians enables us to provide the best possible service and outcome for our patients, across multiple disciplines."
Researchers from the School of Veterinary Sciences at the University of Bristol have had a study into domestic dogs' fear responses to noise published in Applied Animal Behaviour Science.
According to the University, the study provides an important insight into dogs' fear of noises, and could improve our understanding of behavioural signs of fear or anxiety.
In the study two approaches were taken to investigate the occurrence of, and risk factors for, behaviours caused by a fear of noise: a postal survey of dog owners to investigate general demographic factors and a structured interview of a sub-set of owners to gather more detailed information.
It seems that while owners are often aware of their pet's behavioural response when exposed to a loud noise, they do not necessarily recognise it as being indicative of fear or anxiety. This has relevance both for awareness of compromised welfare, and the methodology for surveying such behaviour.
According to the researchers, other behavioural signs, such as decreased activity or salivation, may not be as easily recognised by owners as signs of fear, and may be under-reported. Also, signs of urination, salivation and destruction may make owners disappointed or angry, and this may influence their interpretation that such behaviours are associated with fearfulness.
The risk factors for owner-reported fear of noises included:
The researchers suggest a dog's early life experience is an important factor in the development of fear responses to specific loud noises.
Dr Rachel Casey, European Specialist in Veterinary Behavioural Medicine and Senior Lecturer in Companion Animal Behaviour and Welfare at Bristol University, said: "Our results suggest that the characteristics of dogs, their early environment, and exposure to specific loud noises are involved in the development of fear responses to noises. Interestingly, less than a third of owners sought professional advice about treatment for their pet's response to noises."
Disappointingly, less than a third of owners currently seek professional advice about treatment for their pet's fear. The researchers recommend there is a need for veterinary surgeons to increase awareness among the general dog owning public that treatment is both available and effective in dealing with fears of loud noises, and to direct them towards appropriate sources of help.
Information for vets and dog owners on finding an expert to help treat behaviour problems including fear of noises can be found at www.rspca.org.uk/findabehaviourist
Paper: Fear responses to noises in domestic dogs: Prevalence, risk factors and co-occurrence with other fear related behaviour, Emily J. Blackwell, John W.S. Bradshaw, Rachel A. Casey, Applied Animal Behaviour Science, published online 22 January 2013.
Defra Minister David Heath has announced the latest bute (phenylbutazone) test results. The presence of bute has been confirmed in 8 samples out of 206 tests.
Chief Medical Officer Professor Dame Sally Davies has stated that horsemeat containing phenylbutazone presents a very low risk to human health.
Responding to these latest developments the British Veterinary Association (BVA) and British Equine Veterinary Association (BEVA) have issued the following statement:
"The presence of phenylbutazone (or bute) in horses intended for the food chain will be of concern to consumers who rightly expect the UK food chain to be robust. We are grateful to the Chief Medical Officer for clarifying the very low level of risk that this presents to human health and we will work with the FSA and Defra in any way we can to assist their investigations into these incidents.
"The ability to treat horses with bute is very important for equine welfare. Bute provides affordable, long-term pain relief for horses and is unique in this respect.
"The UK Horse Passport Regulations are designed to facilitate the ongoing medical treatment of horses not intended for the human food chain, whilst ensuring that these animals do not enter the food chain.
"We fully support the concept of the Horse Passport Regulations but have argued for some time that there are problems with the system in terms of the number of Passport Issuing Authorities and the vulnerability of the system to fraud. We are very keen to continue our dialogue with Defra and others to find ways to make the system more robust.
"Our members are aware of the strict rules regarding the regulation of medicines (including bute) and the use of horse passports, and in recent years we have provided clear guidance on the regulations to help both vets and their clients. These incidents will hopefully reinforce these messages amongst horse owners and all of us involved in equine healthcare."
Guidance notes are available via the BEVA website Medicines Page (http://www.beva.org.uk/useful-info/Vets/Guidance/Medicines)
The Advertising Standards Authority has decided not to uphold complaints against the Morrisons Christmas TV advertisement.
The full adjudication can be read here.
Peter Jones, President of the British Veterinary Association, said: "This ruling is disappointing but the ASA has set out its reasons for the decision and we accept those reasons. Thankfully, the advert only had a short shelf life and we hope that Morrisons is now very unlikely to make the same mistakes again. Overall, we hope the whole incident has served to educate Morrisons and the general public about the dangers of grapes and raisins to dogs."
Invicta Animal Health has been appointed exclusive UK distributor of EquiChek, a rapid screening test which uses whole blood to assess the level of Serum Amyloid A (SAA), a major acute phase protein of inflammation in horses.
According to the company, EquiChek is the first test which is able to provide a visual semi-quantitative result within 15 minutes. The test will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Rob Watkins, Managing Director of Invicta, said: "Monitoring SAA levels in horses is a well-documented method of indicating a variety of conditions and for assessing health/inflammatory status prior to performance. However, the needs for equipment and time to perform the tests have always limited the situations in which it can be used.
"EquiChek changes all that. A stableside test for SAA means that monitoring real-time becomes a reality. Whether for tailoring antibiotic therapy, to check pre-breeding health status through to pre-competition health assessment, the applications are literally endless".
For further information see www.invictavet.com or phone 01403 791313
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
The British Small Animal Association has responded to Defra's statement on compulsory microchipping.
The Association says it is an advocate of compulsory microchipping as the most effective way to permanently identify a dog - as long as owners maintain an up-to-date registration on the various databases. As such it broadly welcomes the recent Defra statement.
However, BSAVA points out that the statement has come before a full and considered consultation in terms of its implementation, and says it raises a number of questions for vets in practice:
Despite the headlines around the statement, this is yet to be laid down in law and will require changes under the Animal Welfare Act and potentially the Dangerous Dogs Act, so there is still a conversation to be had about its implementation.
For this reason BSAVA has announced that it is launching a consultation with its members to establish their concerns and opinions in order to work with all the organisations involved in the best interest of animal welfare and the profession. If anyone in practice wants to feed into this consultation, they should visit http://www.bsava.com or contact BSAVA's Scientific Policy Officer Sally Everitt via email - s.everitt@bsava.com.
BSAVA President Mark Johnston said: "While implantation can be straightforward for those with appropriate experience it will be important to ensure that all those who carry out implantation are properly trained. However microchipping is not just a matter of implanting the microchip, there is a significant amount of administrative work in ensuring that animals are properly registered and that details are kept up-to-date. All of these stages need to be properly funded if the scheme is to be successful and sustainable. BSAVA will be consulting its members to gather their views and concerns and hope to be involved in a productive conversation with all interested parties."
BSAVA says there is a good news animal welfare story within this statement concerning the seizure of animals during investigation under the Dangerous Dogs Act. The new measures will allow the authorities to decide whether a suspected prohibited dog can stay with their owners until the outcome of court proceedings. Until now all such animals had to be kennelled until the proceedings had concluded, which often means that dogs who posed no risk suffered unnecessarily. BSAVA welcomes this new measure in the interest of animal welfare.
The Department for Environment, Food and Rural Affairs (Defra) and the Food Standards Agency (FSA) are reminding veterinary surgeons of their legal responsibilities under the Horse Passport Regulations 2009.
The move follows a small number of horses testing positively for the presence of phenylbutazone, which, if consumed, can be harmful to human health.
Defra and the FSA have asked for the assistance of the profession in ensuring that treatment with phenylbutazone is properly recorded in Horse Passports and have said that they are working together to understand the cause of the positive tests, and what longer term measures can be put in place to stop this happening.
In the interim, all horses slaughtered for human consumption will be sampled for the presence of phenylbutazone, with immediate effect.
The letter from Defra and the FSA can be downloaded from the RCVS website.
The full advice can be read in a Veterinary Medicines Directorate/Defra leaflet, which can be found online at http://www.vmd.defra.gov.uk/pdf/leaflet_horses.pdf.
Mark Bowen, Chair of the British Equine Veterinary Association's Health and Medicines Committee, said: "The number of horses entering the human food chain from the UK has doubled since 2009 and is no longer an insignificant minority of horses. All vets should be checking horse passports and only dispensing sensible quantities of this drug, and its prodrug suxibuzone."
Meanwhile, a form is available from the British Equine Veterinary Association website for veterinary surgeons to use if the horse passport is not available, but emergency treatment is required: http://www.beva.org.uk/_uploads/documents/emergency-treatment-form-no-passport-2011.pdf
The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).
Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.
"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.
"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.
"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."
Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.
"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.
"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."
Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."
According to the company, the new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM). Twelve hours after the injection is administered, treatment can be continued by the dog's owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
Ruth Willis BVM&S DVC MRCVS, RCVS Recognised Specialist in Cardiology said: "Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM."
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25 kg.
In association with the Vets Now emergency treatment service, Boehringer has produced an algorithm which features step-by-step guidance on the recommended treatment protocol for dogs with acute congestive heart failure due to MVD or DCM, together with point of sale material including shelf wobblers for use in practice to raise awareness of the product.
The company is also hosting a free cardiology webinar presented by Ruth Willis entitled 'Acute CHF - a stress free approach'. The online seminar takes place at 8.00pm on Tuesday 19 February and counts for one hour's CPD. The webinar will be available to view after the live event on demand. To register, visit http://www.bi-academy.co.uk/.
For further information, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
The Government has announced that from 6 April 2016 all dogs will be required to have a microchip.
This will give owners 3 years to comply with new legislation being drafted by Defra.
According to Defra, 100,000 dogs are dumped or lost each year at a cost of £57 million to the taxpayer and welfare charities. Only 60% of the 8 million dogs in the UK are currently chipped.
Making microchipping compulsory is intended to help reunite owners with lost or stolen pets, relieve the burden on animal charities and local authorities and protect the welfare of dogs by promoting responsible dog ownership.
Owners will be able to get their dog microchipped free at any of the 18 Dogs Trust centres around the UK, and free microchips will be offered by Dogs Trust to local authorities, housing associations and veterinary surgeries. In addition Battersea Dogs and Cats Home has announced that free microchipping will be offered at its three centres, and the Blue Cross will also offer free microchipping to dogs and cats at its 16 hospitals and centres across England.
Veterinary associations have hailed the introduction of compulsory microchipping for all dogs in England as a giant leap forward for dogs and their owners. BVA President Peter Jones said: "The introduction of compulsory microchipping is a giant leap for dogs and their owners and is something that vets have long campaigned for. Microchipping is a safe and effective way to link dogs to their owners and is an essential part of responsible ownership."
The Government also announced plans to extend the scope of the Dangerous Dogs Act to private places and to allow police to decide if dogs seized under the Act can stay with their owners until the outcome of the court case, removing the need for these dogs to be kennelled. Both of these measures were supported by BVA and BSAVA in joint responses to the Defra consultation.
Nominees for the RCVS Council and its Veterinary Nurses Council have been announced, with 13 candidates for the former and four for the latter.
The nominations closed on 31 January, and the following are standing:
RCVS Council
* denotes current RCVS Council member
VN Council
* denotes current VN Council member
Dechra Veterinary Products has relaunched Oxyglobin after concluding an exclusive agreement to supply the product across the UK and Republic of Ireland.
Oxyglobin is used to stabilise anaemic dogs until the underlying condition can be controlled and the animal's body can produce its own new red blood cells.
Dechra says the treatment, which is now available in both 125ml bags and individual 60ml transfusion bags, maintains tissue oxygenation even when there is severe stenosis of blood vessels. It has a viscosity which is more than water but less than blood for ease of flow through vessels, and also increases circulatory volume.
Dechra Veterinary Products Brand Manager, Carol Morgan, said: "Veterinary professionals have been waiting for Oxyglobin to come back onto the market for some time and we're delighted to be able to relaunch it in the UK and Republic of Ireland.
"It was withdrawn from the market in 2010 when OPK Biotech acquired the assets of manufacturer Biopure Corporation in 2009. But this year, OPK Biotech resumed the manufacture of Oxyglobin and we have stocks available to practices from this month (FEB)."
"Oxyglobin turns around clinical outcomes for dogs with anaemia, regardless of the cause of the condition, which is why it is the objective choice for safety, effectiveness and convenience.
"Oxyglobin is the only oxygen-carrying fluid available off the shelf for dogs in need of oxygen support and no typing or cross-matching of the recipient's blood is required."
Oxyglobin, a sterile formulation of polymerised purified bovine haemoglobin in a balanced salt solution with proven efficacy, is available in single dose 60ml and 125ml infusion bags.
For further information on Oxyglobin, see www.dechra.co.uk
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."